ILKAP is a protein phosphatase 2C that selectively associates with integrin linked kinase, ILK, to modulate cell adhesion and growth factor signaling. We investigated the role of endogenous cellular ILKAP in antagonizing ILK signaling of two key targets, PKB and GSK3b. Silencing of endogenous ILKAP by short interfering RNA (siRNA) stimulated GSK3b phosphorylation at S9, with no effect on PKB S473 phosphorylation. In LNCaP prostate carcinoma cells, transient or stable expression of ILKAP suppressed ILK immune complex kinase activity, demonstrating an interaction between ILKAP and ILK. Consistent with the silencing data, ILKAP inhibition of ILK selectively inhibited S9 phosphorylation of GSK3b without affecting S473 phosphorylation of PKB. The ILKAP-mediated inhibition of S9 phosphorylation was rescued by overexpression of ILK, but not by a dominantnegative ILK mutant. The expression level of cyclin D1, a target of ILK-GSK3b signaling, was inversely correlated with ILKAP protein levels, suggesting that antagonism of ILK modulates cell cycle progression. ILKAP expression increased the proportion of LNCaP cells in G1, relative to vector control cells, and siRNA suppression of ILKAP increased entry of cells into the S phase, consistent with ILK antagonism. Anchorage-independent growth of LNCaP cells was inhibited by ILKAP, suggesting a critical role in the suppression of cellular transformation. Taken together, our results indicate that endogenous ILKAP activity inhibits the ILK-GSK3b signaling axis, and suggest that ILKAP activity plays an important role in inhibiting oncogenic transformation.
Introduction
Integrin linked kinase (ILK) is serine/threonine protein kinase that when overexpressed induces properties of transformation in epithelial cells, such as anchorageindependent growth (Hannigan et al., 1996; Radeva et al., 1997) and tumorigenicity in nude mice (Wu et al., 1998) , as well as inducing mammary tumors in transgenic mice (White et al., 2001) . Consistent with these transformation models, elevated ILK protein and activity levels are seen in Ewing's Sarcoma (Chung et al., 1998) , and in precancerous colonic polyps (Marotta et al., 2001) . Elevated ILK expression and activity shows a strong positive correlation with prostate tumor grade (Graff et al., 2001) , is associated with metastatic gastric carcinoma (Ito et al., 2003) and correlates with poor patient outcome in malignant melanoma (Dai et al., 2003) , altogether suggesting that ILK dysregulation contributes to early and late stages of tumor development. At a molecular level, ILK coordinates signal transduction by integrins and growth factor receptors, regulating protein kinase cascades important to cell proliferation, differentiation and apoptosis Dedhar, 2000) . Extracellular signals stimulate ILK in a phosphoinositide-3 0 -OH kinase (PI3K)-dependent manner, involving activation of ILK by direct interaction with lipid products of PI3K activity (Delcommenne et al., 1998 ) also elevated in many cancers. Downregulation of ILK activity by small molecule inhibitors or dominant-negative mutants suppresses ILK-mediated transformation (Persad et al., 2000 (Persad et al., , 2001a Troussard et al., 2000) . Loss of integrin-mediated cell adhesion reduces ILK activity and induces caspasedependent anoikis in epithelial cells . Two key targets of ILK are the serine/threonine kinases, PKB and glycogen synthase kinase 3b (GSK3b) (Delcommenne et al., 1998) , both of whose activities affect cell proliferation and apoptosis (Coffer et al., 1998; Kim and Kimmel, 2000) . ILK mediates phosphorylation of PKB on S473 and GSK3b on S9, and silencing of ILK expression inhibits these two phosphorylations (Troussard et al., 2003) . Interestingly, ILK-stimulated S473 phosphorylation activates PKB to protect cells against anoikis , while S9 phosphorylation of GSK3b inhibits its proapoptotic function (Cross et al., 1995) and correlates with ILK-stimulated cyclin D1 expression (D'Amico et al., 2000) , suggesting that each of these pathways contributes to ILK-mediated oncogenesis.
Physiologic inhibition of ILK signaling is not well understood. The inositol lipid phosphatase, PTEN, is the major cellular antagonist of PI3K activity Dixon, 1998, 1999; Downes et al., 2001) , and has been shown to inhibit ILK activity and signaling. Reconstitution of PTENÀ/À prostate carcinoma cells reverts constitutively elevated ILK activity, as well as PKB S473 and GSK3b S9 phosphorylation states, to normal levels (Persad et al., 2000 (Persad et al., , 2001b . Thus, the PTEN tumor suppressor indirectly inhibits ILK signaling of the two protein kinases.
We have recently described the direct association of ILK with ILKAP, a serine/threonine protein phosphatase. ILKAP was identified in a yeast two-hybrid screen for ILK binding proteins, and subsequently found to form cytoplasmic complexes with ILK. The conditional expression of ILKAP selectively inhibits ILK signaling of GSK3b and b-catenin, important activities in the Wnt signaling pathway, without affecting ILK-mediated PKB phosphorylation (Leung-Hagesteijn et al., 2001) . Dyrsegulation of Wnt pathway constituents is widely implicated in the development of cancers (Barker and Clevers, 2000; Polakis, 2000) and also attends ILK overexpression in cells and tumors (Novak et al., 1998; Novak and Dedhar, 1999; White et al., 2001) , suggesting regulation of Wnt signaling by ILK-ILKAP complexes. Importantly, with regard to ILKAP specificity, expression of the highly related PP2Ca isoform does not inhibit bcatenin signaling (Leung-Hagesteijn et al., 2001) , and in fact PP2Ca stimulates this pathway (Strovel et al., 2000) .
ILK-mediated inhibition of GSK3b in epithelial cells induces expression of the G1 cyclin, D1, with resultant stimulation of cdk4 activity and S-phase entry (Radeva et al., 1997; D'Amico et al., 2000) . In the transgenic mouse model of ILK mammary carcinoma, tumors display increased levels of PKB pS473 and GSK3b pS9 as well as increased cyclin D1 expression (White et al., 2001) , recapitulating molecular changes in vitro during ILK-mediated transformation. In the present study, we investigated the contribution of endogenous ILKAP to the regulation of ILK-GSK3b signaling as well as the role of ILKAP to suppress ILK signaling in the absence of PTEN, an indirect ILK inhibitor. siRNA-mediated ILKAP suppression increased phosphorylation of GSK3b on S9, while expression of ILKAP in PTENÀ/ À LNCaP cells inhibited S9 phosphorylation. Manipulation of ILKAP protein levels did not alter PKB phosphorylation at S473, indicating that endogenous ILKAP selectively regulates the ILK-GSK3b signaling axis. Suppression of endogenous ILKAP also decreased the proportion of cells in G1, inducing cyclin D1 expression and entry of cells into the S phase. Importantly, ILKAP expression inhibited anchorage-independent growth of LNCaP cells, suggesting a potential tumor suppressor role. Taken together, our data indicate that ILKAP is a physiologic inhibitor of ILK-GSK3b signaling, and suggest a role in suppressing ILK oncogenesis.
Results

Endogenous ILKAP selectively modulates GSK3b S9 phosphorylation
As we previously reported that ILKAP expression in HEK293 cells antagonizes ILK signaling, we wished to study the role of endogenous ILKAP in these cells. Also, in light of the work showing indirect inhibition of ILK by PTEN, we felt it important to examine the ability of ILKAP to inhibit ILK signaling independent of PTEN activity. For this purpose, we employed PTEN-deficient LNCaP prostate carcinoma cells, either transiently or stably transfected with an EGFP-ILKAP expression vector (constructed for subcellular localization studies to be reported elsewhere). Western blots confirmed similar levels of endogenous ILKAP and ILK in the HEK293 and LNCaP cells (not shown).
To examine the regulation of ILK signaling by endogenous ILKAP, we designed ILKAP-specific siRNAs, and transfected 10 and 25 nM of each into HEK293 cells. At 72 h post-transfection, cytoplasmic lysates were assayed for ILKAP expression by Western blotting with a purified polyclonal ILKAP antibody. Densitometry indicated that 10 nM of siRNA was most efficient in suppressing ILKAP protein levels (485%), with no effect on the levels of ILK or an irrelevant control, GAPDH ( Figure 1a) . Similarly, siRNAmediated suppression of ILK (480% inhibition) had no effect on ILKAP or GAPDH protein levels ( Figure 1b) . Finally, transfection of 1-10 nM GAPDH siRNA resulted in a dose-dependent suppression of GAPDH, but not b-actin or ILKAP protein expression (Figure 1c) , confirming the specificity of the siRNAs. These results demonstrate that cellular levels of ILK and ILKAP are independent of one another.
Having validated our siRNAs, we determined next to examine the effects of ILKAP silencing on ILK targets. First, we analysed the phosphorylation status of GSK3b at S9 and PKB at S473, in ILKAP-suppressed and nonsuppressed HEK293 cells (constitutively elevated ILK signaling in LNCaP cells precluded their use in similar ILKAP siRNA). The phosphorylation of two cellular ILK targets, PKB and GSK3b, was analysed in the lysates of ILKAP-suppressed cells. Phosphorylation of GSK3b at S9 was selectively increased in ILKAP suppressed cells, with no change in the PKB pS473 level (Figure 2a ). ILK siRNA experiments confirmed that these phosphorylations were significantly inhibited in ILK suppressed cells, as reported by others (Troussard et al., 2003) , demonstrating an ILK requirement for these events (not shown). ILK activity in epithelial cells upregulates cyclin D1 in a GSK3b-dependent manner (D'Amico et al., 2000) ; therefore, we also analysed lysates of ILKAP-suppressed cells for the expression of cyclin D1. Consistent with the increased S9 phosphorylation, ILKAP suppression increased cellular levels of cyclin D1 protein (Figure 2a ), suggesting regulation of an ILK-GSK3-cyclin D1 axis. For controls, Western blots confirmed unaltered ILK, PKB or GSK3b protein levels in either ILKAP-or GAPDH-silenced cells (Figure 2 ). These results establish that endogenous cellular ILKAP selectively regulates ILKGSK3b signaling, without affecting the ILK-PKB axis.
ILKAP inhibits ILK signaling in PTENÀ/À LNCaP cells
We have previously reported that ILKAP inhibition of ILK-GSK3b signaling in PTEN expressing HEK293 cells (Myers et al., 1998; Leslie et al., 2000) requires ILKAP catalytic activity (Leung-Hagesteijn et al., 2001) . In order to determine whether acute expression of ILKAP inhibits ILK signaling in a PTENÀ/À background, we examined the phosphorylation of PKB and GSK3b in LNCaP cells transiently transfected with increasing amounts of EGFP-ILKAP expression vector. EGFP-ILKAP, but not the EGFP vector control, caused a dose-dependent inhibition of GSK3b S9, again with no effect on PKB S473 phosphorylation ( Figure 3 ). These results indicate that ILKAP selectively targets GSK3b in LNCaP cells; thus we conclude that ILKAP can downregulate ILK-GSK3b independent of PTEN.
In order to examine the inhibition of ILK activity and downstream signaling, we derived stable cell lines from LNCaP transfected with EGFP-ILKAP (LNCaP-ILK-AP) as well as an empty vector control (LNCaP-ev). To avoid potential clonal variations, we selected uncloned lines for study. Western blot analyses of LNCaP-ILKAP and LNCaP-ev cells, with purified anti-ILKAP and After 48 h, the phosphorylation of ILK targets was assessed by Western blotting using phospho-specific antibodies for GSK-3b pS9 and PKB pSer 473. Blots were stripped and reprobed for the total levels of GSK3b, PKB, ILKAP and b-actin loading control. Results represent two independent determinations Densitometry of ILKAP bands consistently showed X 85% suppression, relative to controls. Blots were stripped and sequentially reprobed with ILK and GAPDH antibodies. Indicated concentrations of (b) ILK siRNAs (ILK1, ILK2, and ILK3 are defined in Materials and methods) and (c) GAPDH siRNAs were transfected into HEK293 cells. After 72 h, protein levels were assessed by Western blotting using the indicated antibodies. In (b), the apparent increased mobility in the first lane is an atypical gel artifact. siRNA results represent at least two independent determinations GFP antibodies, confirmed appropriate expression of the recombinant protein (Figure 4a ). We found significantly reduced ILK activity in LNCaP-ILKAP cells, relative to controls (Figure 4b ), as we have also reported for HEK293 cells (Leung-Hagesteijn et al., 2001) .
ILK inhibition of GSK3b induces cyclin D1 expression (Radeva et al., 1997; D'Amico et al., 2000) ; therefore, we examined the effects of altered ILKAP expression on the levels of cyclin D1 protein in LNCaP-ILKAP cells. Consistent with ILKAP antagonism of ILK, cyclin D1 expression was significantly reduced in the stable LNCaP-ILKAP, relative to LNCaP-ev cells, while levels of two control proteins, E-cadherin and bactin, were not affected (Figure 4a) . In order to test for acute regulation of cyclin D1, we analysed LNCaP cells transiently transfected with increasing concentrations of the EGFP-ILKAP plasmid. Cyclin D1 protein level, but not E-cadherin or b-actin expression, was decreased in an ILKAP dose-dependent manner, 48 h post-transfection. Consistent with a report of ILK-mediated downregulation of the cyclin-cdk inhibitor p27
kip (Radeva et al., 1997) , ILKAP also induced a modest increase in the levels of p27 kip (Figure 4c ), further suggesting ILK antagonism.
Since increasing the expression levels of ILKAP suppresses ILK activity, we reasoned that overexpression of ILK would rescue this suppression. For these studies, we constructed adenoviruses for high-level expression of active, wild-type ILK and an inactive ILK(R211A) mutant (Persad et al., 2001a) . LNCaP-ILKAP cells infected with either virus exhibited a similar level of ILK overexpression; however, only Ad-ILK stimulated phosphorylations of PKB and GSK3b ( Figure 5 ). This rescue further demonstrates a functional ILKAP-ILK interaction, and also emphasizes the importance of ILK catalytic activity in downstream signaling.
ILKAP inhibits cell cycle and anchorage-independent growth of LNCaP cells
The observed ILKAP effects on cyclin D1 levels suggested the modulation of cell cycle progression, and we predicted an increase in the proportion of LNCaP-ILKAP cells in the G1 phase, relative to LNCaP-ev. As assayed by flow cytometry, LNCaP-ILKAP cultures showed an 18% increase in the proportion of cells in G1, relative to LNCaP-ev cells (Table 1, Figure 6a ). These results demonstrate that ILKAP expression inhibits Sphase entry, and we then analysed cell cycle effects of ILKAP suppression in HEK293 cells. Consistent with the above data, siRNA-mediated ILKAP suppression caused a 10% decrease in the G1 cell population, and a 6% increase in S-phase cells, relative to unsuppressed controls (Table 1, Figure 6b ).
Our previous work implicated ILKAP in the negative regulation of cell adhesion signaling (Leung-Hagesteijn et al., 2001) ; therefore, we wished to examine the potential functions of ILKAP in regulating anchorageindependent growth. HEK293 cells do not form colonies (data not shown); however, LNCaP are highly transformed and clonogenic in soft agar (Wan et al., 2003) . The mean number of LNCaP and LNCaP-ev colonies after 4 days of culture was 5973 and 5672, respectively, compared to 2473 LNCaP-ILKAP colonies (Figure 6c) , reflecting approximately 60% inhibition by ILKAP. These results suggest that ILKAP downregulation of ILK signaling contributes to the inhibition of the oncogenic phenotype. 
Discussion
The data presented here demonstrate that endogenous ILKAP regulates ILK activity and signaling and, moreover, that this regulation suppresses the oncogenic phenotype of PTEN null prostate carcinoma cells.
ILKAP (also called PP2Cd, (Tong et al., 1998) belongs to a conserved subfamily of PP2C enzymes implicated in the regulation of signal tranduction, and which usually account for less than 10% of cellular serine/threonine phosphatase activity (DePaoli-Roach et al., 1994) . Unlike the more abundant serine/threonine The percentage of indicated cell population in each phase of the cell cycle was determined from FACS analyses, shown in Figure 6a and b Figure 6 ILKAP modulates cell cycle progression and anchorage-independent growth. (a) LNCaP-ILKAP and LNCaP-ev cells were analysed for cell cycle DNA content as described in Materials and methods. (b). HEK293 were analysed for cell cycle by flow cytometry, as in (a), 72 h after transfection of ILKAP siRNA. The subdiploid peak is an artifact of siRNA transfection, probably due to the presence of dsRNA, since control siRNA induced the same peak. Each panel is representative of two independent analyses. (c) LNCaP, LNCaP-ILKAP and LNCaP-ev cells were grown in soft agarose to assess anchorage-independent growth. For each determination, colonies were counted in 12 wells, and reported as mean colonies per microscope field (see Materials and methods). This experiment was carried out twice independently, and results were pooled from the two determinations (n ¼ 24)
phosphatases, such as PP1 or PP2A, PP2Cs are functional monomers with regulatory and catalytic activities resident in the same polypeptide chain (DePaoli-Roach et al., 1994; Das et al., 1996; Barford et al., 1998; Janssens and Goris, 2001 ). PP2C family members regulate diverse cellular functions in a variety of organisms. PP2C isoforms regulate cell cycle transit through dephosphorylation of cdc28p, the major cyclin dependent kinase of budding yeast (Cheng et al., 1999) . The relatively modest effect of ILKAP on cell cycle progression in our studies indicates that it is not likely a direct regulator of CDK activity; however, our results suggest the modulation of cyclin D1/cdk4 activity by ILK/ILKAP complexes. The complementary effects of ILKAP expression and silencing on cyclin D1 also suggest that it affects D1 levels through the regulation of GSK3b activity. GSK3b-mediated phosphorylation of cyclin D1 at T286 promotes its nuclear export and cytoplasmic proteolysis (Diehl et al., 1998) , and the expression of a T286A mutant D1 protein results in nuclear accumulation and oncogenic transformation of NIH 3T3 fibroblasts (Alt et al., 2000) . Our data, showing that loss of endogenous ILKAP increases inhibitory GSK3b phosphorylation at S9 and also cyclin D1 expression, suggest that ILKAP inhibition of ILK promotes GSK3b-dependent T286 phosphorylation, nuclear export and proteolysis of cyclin D1. Dysregulation of ILKAP could thereby underlie the progression of tumors exhibiting elevated cyclin D1 levels (Diehl, 2002) , and it will be important to determine if ILKAP expression is downregulated by these tumors. PP2C enzymes regulate signal transduction pathways in yeast (Marsolier et al., 2000) , plants (Rodriguez, 1998) , invertebrates ) and vertebrates (Barford et al., 1998) . In humans, PP2Ca has been shown to associate with and inhibit p38 MAPK signaling (Takekawa et al., 1998) , analogous to what we have shown with ILKAP and ILK. PP2Ca also activates Wnt signaling by complexing with and dephosphorylating Axin (Strovel et al., 2000) ; thus PP2Ca and ILKAP play opposing roles in signaling transcription by b-catenin and TCF/Lef factors. POPX1 and POPX2 are PP2C isoforms that inactivate p65 PAK (Koh et al., 2002) . Interestingly, POPX1 and POPX2 are direct binding partners for PIX proteins, Rho family GTPase exchange factors that regulate p65 PAK activity and actin reorganization (Manser et al., 1998) . Moreover, a-PIX has recently been shown to interact with the ILK binding adaptor, b-parvin (Rosenberger et al., 2003) , suggesting that ILKAP interacts with ILK and b-parvin to regulate actin remodeling. Consistent with this, using immunocytochemistry and GFP fusion proteins, we observe abundant colocalization of ILK, ILKAP and b-parvin in the leading edge of migrating myoblasts (P Wang, G H, unpublished). Thus, ILKAP may function in multiple subcellular compartments, acting more broadly to inhibit ILK-dependent processes.
We have not identified the substrate for ILKAP catalysis that underlies downregulation of ILK-GSK3b signaling; however, various lines of evidence argue against direct action on GSK3. First, ILKAP and ILK interact directly in two hybrid assays, and are coprecipitated from cell lysates. Second, induction of ILKAP catalytic activity acutely inhibits ILK immune complex kinase activity (Leung-Hagesteijn et al., 2001) . Third, silencing of ILKAP expression increases phosphorylation at S9 (Figure 2) , indicating a target protein kinase upstream of GSK3b. Finally, overexpression of active, but not inactive ILK reverses ILKAP-mediated suppression of pS9 (Figure 5 ), supporting the interaction of ILKAP with ILK, rather than with GSK3b. We note that S343 in the putative activation loop of ILK is a strong candidate substrate, since substitution of a negative charge at this site results in the constitutive activation of ILK signaling (Persad et al., 2001a) . Thus, our data indicate that endogenous ILKAP likely regulates signaling through direct action on ILK.
ILK activity is rapidly and transiently induced in response to ligand engagement of growth factor receptors or integrins. Inositol lipids, such as PIP3, activate ILK through interaction with a pleckstrin homology-like domain located in the central region of ILK (Delcommenne et al., 1998) . PTEN-mediated dephosphorylation of PIP3 indirectly downregulates ILK activity and its downstream targets, including PKB and GSK3b (Morimoto et al., 2000; Persad et al., 2000 Persad et al., , 2001b . Stomach-associated protein phosphatase 1 (SAP-1) is a transmembrane protein tyrosine phosphatase that downregulates integrin signaling, by dephosphorylating focal adhesion proteins such as p130 Cas (Noguchi et al., 2001) , also inducing caspase-dependent apoptosis through inhibition of ILK-PKB signaling (Takada et al., 2002) . Integrin-dependent modulation of the serine/threonine phosphatase activity of PP2A has been shown to inhibit PKB S473 and GSK3b S9 phosphorylations (Ivaska et al., 2002) , and although not implicated, may also indirectly affect ILK signaling. Altogether, the available data point toward downregulation of ILK activity by multiple, lipid and protein phosphatases, affecting different targets upstream of ILK (Figure 7 ). Given their direct interaction, the selective downregulation of one arm of ILK signaling by ILKAP is striking, and suggests additional levels of regulation. Other outstanding questions relate to the modulation of ILKAP activity by extracellular signals, and the extent to which ILKAP is downregulated in cancers. 
Materials and methods
Cell culture and transfections
HEK 293 cells were cultured in high glucose, Dulbecco's modified Eagle's medium (DMEM) (Invitrogen), supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and 0.1 mM nonessential amino acids (Invitrogen). LNCaP cells were cultured in RMPI 1640 media supplemented with 10% FCS.
HEK293 cells were transfected with in vitro transcribed siRNA molecules (see below) using Lipofectamine 2000 (Invitrogen), according to the manufacturer's guidelines for DNA transfection. Stable transfectant derivatives of LNCaP were selected in 0.8 mg/ml Geneticin G418 (Invitrogen) for 3-4 weeks. EGFP fusion protein expression was monitored by Western blotting with monoclonal GFP antibody, or by fluorescence confocal microscopy.
Synthesis of short interfering RNA molecules
Single-stranded siRNA were transcribed and annealed using a commercial kit, as outlined in the supplier's manual (Silencer Kit, Ambion). The following sequences were used to construct ILKAP and ILK siRNA.
ILKAP360
:
GAPDH control siRNA was provided with the Silencer siRNA construction kit. Each sequence was confirmed as unique, using the BLAST algorithm (Altschul et al., 1990) .
Cell cycle analysis
Asynchronously growing cells were trypsinized and 1 Â 10 6 cells were washed with ice-cold Hank's Balanced Salt Solution (HBSS, Invitrogen) supplemented with 2% FCS, fixed in 70% ethanol for 1 h and rinsed with HBSS. DNA was stained with 0.1 mg/ml propidium iodide in PBS containing 10 mg/ml RNase for 30 min in the dark at room temperature. Cell cycle profiles were immediately analysed by FACS using a Becton Dickinson FACScan analyser. DNA ploidy and cell cycle distribution were calculated using CellFit software.
Colony growth in soft agarose
In total, 1.5 Â 10 5. cells were placed in RPMI 1640 (10% FCS) in 0.3% (w/v) low melting point agarose, on a layer of RPMI 1640 (10% FCS) in 0.5% LMP agarose. After 4 days, colonies in the upper agarose layer containing 45 cells were counted. The results represent mean colonies per microscope field at Â 10 magnification (n ¼ 12).
Western blot analysis of total and phosphorylated proteins
For protein analyses, 10% SDS-PAGE gels were used to resolve 10 mg cellular protein per lane. Proteins were then electrophoretically transferred onto polyvinyldifluoride membranes (Immobilon-P, Millipore) and processed for Western blotting as described previously (Leung-Hagesteijn et al., 2001) . Affinity purified polyclonal rabbit antibodies were purchased from commercial sources: ILK, phospho-PKB S473 and phospho-GSK3b S9 (Cell Signaling). The following commercial mouse monoclonal antibodies were used: GSK-3a/ b (Upstate Biotechnology), GAPDH (Ambion), cyclin D1 (Oncogene Research), GFP (Santa Cruz), b-actin (Sigma), Ecadherin and PKB (Transduction Labs) and p27 kip1 (BD Biosciences). We generated an ILKAP polyclonal antibody, using glutathione-S-transferase-ILKAP fusion protein (GST-ILKAP) as immunogen. For purification of the immunogen, GST-ILKAP protein was thrombin-cleaved, and full-length ILKAP was purified by dialysis in PBS followed by SDS-PAGE and electro-elution. New Zealand white rabbits received three injections of 0.5 mg of soluble ILKAP protein. Serum was collected 3-6 week postimmunization and the IgG fraction was purified using the Protein A Purification Kit (Pierce Biochemical). Secondary antibodies of either horse radish peroxidase-conjugated goat anti-rabbit, or rabbit antimouse (Jackson ImmunoResearch), were incubated at 1 : 2000 dilutions in 5% PBST-MILK, for 1 h at room temperature. Bands were visualized with chemiluminescent substrate (ECL, Amersham), and quantitated by on-line densitometry (www.scioncorp.com). PVDF membranes were washed 3 Â 5 min with PBST after primary and secondary incubations. For sequential reprobing, blots were stripped and reblocked as described (Leung-Hagesteijn et al., 2001) ; however, phosphospecific antibodies were used only on nonstripped membranes.
ILK immune complex kinase assay
ILK immune complex kinase assays were performed as described previously (Leung-Hagesteijn et al., 2001) . Briefly, 0.2-0.5 mg of NP-40 lysates were immunoprecipitated with 2 mg of affinity purified rabbit anti-ILK 592 antibody (UBI) overnight at 41C with rotation. Protein A-Sepharose (Sigma), preswollen in NP-40 lysis buffer, was added for 2 h at 41C to capture the antibodies. Immune complex kinase activity was assayed on exogenous myosin light-chain substrate (MLC 20 ).
Adenovirus construction and purification
Adenoviral recombinants were generated using the AdEasy Adenoviral Vector System, following the manufacturer's guidelines (Stratagene). Briefly, wild-type or mutant (R211A) ILK cDNA was cloned into the AdEasy shuttle vector pAdTrack-CMV. The resultant plasmids were cotransformed with the adenoviral backbone plasmid pAdEasy-1 into BJ5183 strain of E. coli. Recombinant adenoviral plasmids were selected on kanamycin and accuracy was confirmed by restriction digests and DNA sequencing. Plasmids were then transfected into HEK293 cells (Lipofectamine 2000; according to the manufacturer's instructions) for viral packaging and titering. The resultant Ad-ILK or Ad-R211A-ILK viruses were purified by CsCl banding, providing yields of 2 Â 10 9 , and 3 Â 10 9 plaque forming units/ml, respectively. Multiplicity of infection, MOI, was determined using these titers. Visualization of plasmid encoded GFP by confocal microscopy of adeno-infected LNCaP cells confirmed 100% recombinant expression at an MOI of 5.
